Background Ixekizumab is an interleukin-17A antagonist approved for treatment of moderate-to-severe plaque psoriasis with a recommended 160-mg starting dose, then 80 mg every 2 weeks (Q2W) to week 12, and every 4 weeks (Q4W) thereafter. Objective To evaluate continuous Q2W dosing over 52 weeks. Methods In this phase III, multicentre, double-blinded, parallel-group trial, three ixekizumab dosing regimens were assessed for efficacy and safety at week 52 in patients with moderate-to-severe plaque psoriasis randomized at a 2 : 1 : 1 ratio to continuous Q2W (n = 611), continuous Q4W (n = 310) or dose adjustment per protocol (Q4W/Q2W, n = 306), each with a 160-mg starting dose. Dose adjustment was determined by predefined criteria to which investigators were blinded; 72 (23·5%) patients in the Q4W/Q2W group adjusted dose. Efficacy outcomes were evaluated using logistic regression. Results Co-primary end points were met at week 52: Psoriasis Area and Severity Index 75 responses for Q2W and Q4W dose groups were 85Á9% and 79Á0%, respectively (P = 0Á006), and static patient global assessment 0/1 responses for Q2W and Q4W dose groups were 78Á6% and 70Á6%, respectively (P = 0Á005). Treatment-emergent and serious adverse events were comparable across dose groups. Conclusions Ixekizumab Q2W had higher efficacy at week 52 than ixekizumab Q4W, with no increase in safety events.
What does this study add?
• In this phase III trial, patients with moderate-to-severe psoriasis treated continuously with every-2-week vs. every-4-week ixekizumab had higher efficacy, with comparable safety profiles, at 52 weeks.
Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A and has previously been shown to be efficacious in the treatment of moderate-to-severe plaque psoriasis with significantly higher efficacy than both etanercept and ustekinumab. [1] [2] [3] Based on results of the pivotal phase III UNCOVER trials, 1,2 a starting dose of 160 mg ixekizumab followed by 80 mg every 2 weeks (Q2W) for 12 weeks and every 4 weeks (Q4W) thereafter was selected as the optimal dose (current recommended label dose); however, prior studies of ixekizumab did not evaluate efficacy and safety of Q2W dosing beyond 12 weeks. While the current dose regimen for ixekizumab is highly efficacious for many patients, some may benefit from more frequent dosing beyond 12 weeks. Indeed, results from a clinical trial of ustekinumab suggested that patients and clinicians preferred flexibility in dosing to optimize patient outcomes. 4 This study (IXORA-P) was designed to evaluate the longerterm efficacy and safety of continuous Q2W dosing of ixekizumab. An additional aim of this study was to assess the potential benefit of increasing dose frequency after week 12 to Q2W in patients who have inadequate response to Q4W dosing. At the inception of this trial, the recommended dosing regimen for ixekizumab had not yet been established; consequently, the label dose was not included in this study.
Patients and methods

Patients
This study was conducted in accordance with ethical principles derived from international ethics guidelines, including the Declaration of Helsinki and the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, the International Conference on Harmonisation (ICH) Good Clinical Practices (GCPs) Guideline (E6), and applicable laws and regulations. This trial was registered with clinicaltrials.gov (NCT02513550) and EudraCT (2015-000190-12) . Informed consent forms that were approved by applicable ethical review boards were signed by all patients prior to participating in any protocol procedures and administration of study drug. Eligible participants were 18 years or older, diagnosed with chronic psoriasis for at least 6 months, had at least 10% body surface area involvement, had both a static patient global assessment (sPGA) score ≥ 3 and a Psoriasis Area and Severity Index (PASI) score ≥ 12 at screening and baseline, and were candidates for phototherapy and/or systemic therapy. Complete inclusion and exclusion criteria are available in Appendix S1 (see Supporting Information). The first patient was enrolled on 15 August 2015.
Study design
This multicentre, randomized, double-blinded, parallel group, phase III trial was conducted at 139 study sites across 14 countries (Argentina, Australia, Canada, Czech Republic, Germany, Hungary, Japan, South Korea, Mexico, Poland, Puerto Rico, Romania, Taiwan, and the U.S.A.; see Appendix S1 for complete list of study sites). Assignment to dosing regimens was determined by a computer-generated random sequence using an interactive web response system (IWRS). Patients with moderate-to-severe psoriasis were randomized at a 2 : 1 : 1 ratio [stratified by country and weight (< 80 kg, ≥ 80 to < 100 kg, or ≥ 100 kg)] to receive 80 mg ixekizumab Q2W continuously until week 50, Q4W continuously until week 48 or Q4W to week 48 with a dose adjustment to Q2W until week 50 for patients meeting prespecified criteria to which investigators were blinded (Q4W/Q2W dose adjustment); each with a starting dose of 160 mg (Fig. 1) . Prespecified criteria for patients within the dose-adjustment group were as follows: sPGA score ≥ 2 at two consecutive monthly visits would result in dose adjustment from Q4W dosing to Q2W dosing, with the dose adjustment window occurring from weeks 16 to 40. To maintain investigator blinding, site personnel entered an sPGA score into the IWRS every 4 weeks, beginning at week 0 through week 48. Two consecutive sPGA scores ≥ 2 entered into IWRS from week 12 to week 40 would result in dose titration/dose adjustment to ixekizumab 80 mg Q2W beginning at week 16. Once a patient had been dose-adjusted to Q2W, the patient would remain on Q2W for the remainder of the study. Note that the results for the dose-adjustment group are presented for all patients in that dose group, regardless of whether their dose was adjusted.
Objectives and assessments
The co-primary objectives of the study were to compare the sPGA 0/1 and PASI 75 (at least a 75% improvement from baseline in PASI) responses at week 52 in the Q2W dose group vs. the Q4W dose group in the treatment of patients with moderate-to-severe psoriasis. Major secondary objectives were to compare 52-week sPGA 0/1 and PASI 75 responses in Q4W/Q2W dose adjustment vs. Q4W dose groups, as well as sPGA 0 responses in Q2W vs. Q4W dose groups. Other secondary outcome measures included percentages of patients achieving PASI 90, PASI 100 (at least 90% and 100% improvement from baseline PASI, respectively), Nail Psoriasis Area and Severity Index (NAPSI) = 0, Palmoplantar Psoriasis Area and Severity Index (PPASI) = 0, Psoriasis Scalp Severity Index (PSSI) = 0, Dermatology Life Quality Index (DLQI) 0/ 1, and ≥ 4 point improvement from baseline itch numerical rating scale (NRS) score in Q2W vs. Q4W dose groups, as well as Q4W/Q2W dose adjustment vs. Q4W dose groups. More detailed descriptions of these outcome measures can be found in Appendix S1.
Investigators monitored safety during the 52-week blinded dosing period, as well as for at least 12 weeks after discontinuation for any reason for any patient who received at least one dose of study drug. Cerebrocardiovascular and inflammatory bowel disease (IBD) events were externally adjudicated. Further details regarding adjudication can be found in Appendix S1 (see Supporting Information).
Statistical analyses
All randomized patients were analysed according to the dose group to which they were assigned (intent to treat), regardless of compliance. Safety analyses were performed for all patients who received at least one dose of study drug.
A sample size of 1200 randomized patients was planned for the study, which provided a range of power from 73% to 93% based on an sPGA (0/1) or a PASI 75 response rate of 80% for the Q4W dosing, and a range of response rates from 87% to 89% for the Q2W dosing at week 52. A two-sided Fisher's exact test at the 0Á05 level was assumed. A graphical multiple-testing procedure was implemented for the primary and major secondary objectives to control the family-wise type I error rate at a two-sided a level of 0Á05. 5 This allowed simultaneous inference of all the primary and major secondary end points. The primary analysis method for categorical binary efficacy measures was logistic regression analysis with dosing regimen, country and baseline weight category (< 80 kg, ≥ 80 to < 100 kg, or ≥ 100 kg) as factors (unless there was a lack of convergence, in which case P-values were calculated using Fisher's exact test). Missing data were imputed as nonresponse (NRI). The multiple imputation (MI) method was also used to impute missing values as a sensitivity analysis, 6 where a sequential regression imputation with the baseline score was implemented. Fisher's exact test was used for comparisons of all categorical safety data.
Results
Patients
In total, 1467 patients were screened for eligibility, and 1227 patients were randomized to ixekizumab Q4W (n = 310), Q4W/Q2W dose adjustment (n = 306) or Q2W (n = 611). The 52-week period was completed by 274 (88Á4%), 268 (87Á6%) and 537 (87Á9%) patients in the Q4W, Q4W/Q2W and Q2W dose groups, respectively. Among the 306 patients randomized to the Q4W/Q2W dose adjustment regimen, 72 (23Á5%) patients met dose-adjustment criteria and the dose was escalated to Q2W during weeks 16-40; 63 (87Á5%) of these patients completed the 52-week period. Among the 234 patients in the Q4W/Q2W dose-adjustment group who did not meet dose-adjustment criteria during weeks 16-40, 205 (87Á6%) patients completed the 52-week period (Fig. 2 ). Efficacy and safety results for the dose-adjustment group were based on all 306 randomized patients. Baseline demographics and clinical characteristics were similar across dose groups, except for age, with a mean age of 47Á4, 49Á0 and 45Á9 years for patients in the Q4W, Q2W, and Q4W/Q2W dose-adjustment groups, respectively (Table 1) .
Efficacy
In brief, high levels of clinical response were achieved and maintained through 52 weeks in all dose groups. However, Q2W dosing provided significantly higher response rates than Q4W dosing. There was no clinically meaningful difference between the Q4W dose group and the dose-adjustment group. The co-primary end points were met; a significantly greater proportion of patients receiving Q2W achieved sPGA 0/1 response compared with those receiving Q4W (78Á6% vs. 70Á6%; P = 0Á005), and a significantly greater proportion achieved PASI 75 response (85Á9% vs. 79Á0%; P = 0Á006) at week 52 ( Fig. 3a, b ; Table 2 ). Among the three major secondary end points, sPGA 0 response rates at week 52 were significantly higher in the Q2W group compared with the Q4W group (60Á1% vs. 44Á8%; P < 0Á001); however, there were no significant differences between Q4W/Q2W doseadjustment group and Q4W group in sPGA 0/1 (72Á5% in the dose-adjustment group) or PASI 75 (83Á7% in the doseadjustment group) responses at week 52 (P = 0Á522 and P = 0Á118, respectively).
At week 52, PASI 90 responses were significantly higher in patients treated with Q2W compared with Q4W (79Á5% vs. 65Á2%, respectively; P < 0Á001). Similarly, PASI 100 response rates were significantly higher in patients treated with Q2W compared with Q4W [59Á7% vs. 43Á5%, respectively; P < 0Á001 ( Fig. 3c, d ; Table 2 )]. While both PASI 90 (73Á9%) and PASI 100 (49Á3%) responses at week 52 were numerically higher in the Q4W/Q2W dose-adjustment group than in the Q4W group, statistically significant differences were seen only for PASI 90 (P = 0Á013). Results for all PASI and sPGA responses imputed with MI were numerically higher than NRI results; nonetheless, MI results generally followed the same pattern of response differences between dose groups as NRI results (Table 2) .
Responses for difficult-to-treat regions and patient-reported outcomes are also provided in Table 2 . At week 52, responses were high and comparable in all dose groups for patients with psoriasis in hard-to-treat regions at baseline (90Á1%, 28Á6% and 57Á3% of patients had scalp, palmoplantar and nail psoriasis, respectively). Significantly higher percentages of patients with baseline scalp psoriasis treated with Q2W dosing (76Á9%) achieved PSSI = 0 compared with patients treated with Q4W dosing (70Á3%; P = 0Á032); there was no significant difference between patients in the Q4W/Q2W doseadjustment group (72Á6%) compared with the Q4W group (P = 0Á475). At week 52, across all three dose groups, 76Á6% of patients with baseline palmoplantar psoriasis achieved Discontinued treatment (n = 36) 11 due to withdrawal by subject 5 due to AE 9 were lost to follow-up 4 due to lack of efficacy 1 due to protocol deviation 2 due to physician decision 1 due to site termination by sponsor 2 due to other 1 due to death Discontinued treatment (n = 74) 25 due to withdrawal by subject 17 due to AE 11 were lost to follow-up 6 due to lack of efficacy 4 due to protocol deviation 4 due to physician decision 3 due to site termination by sponsor 2 due to other 2 due to death Discontinued treatment (n = 29) 5 due to withdrawal by subject 12 due to AE 7 were lost to follow-up 3 due to lack of efficacy 1 due to protocol deviation 1 due to site termination by sponsor British Journal of Dermatology (2018) 178, pp1315-1323 PPASI = 0; there were no significant differences in patients in the Q2W group (P > 0Á999) or the Q4W/Q2W dose-adjustment group (P = 0Á479) compared with those in the Q4W group. Similarly, 53Á1% of patients across all dose groups with baseline nail psoriasis achieved NAPSI = 0; there were no significant differences in patients in the Q2W group (P = 0Á351) or the Q4W/Q2W dose-adjustment group (P = 0Á744) compared with those in the Q4W group. The percentage of patients reporting no impact of psoriasis on their quality of life (DLQI 0/1) 7,8 was significantly higher in Q2W (74Á0%; P = 0Á01) but not in Q4W/Q2W (70Á3%; P = 0Á25) dose groups vs. the Q4W (66Á1%) dose group. Approximately 75% of patients with itch NRS ≥ 4 at baseline experienced at least a 4-point improvement from baseline with no significant differences between dose groups.
Safety
During the 52-week treatment period, the percentages of patients with at least one treatment-emergent adverse event (TEAE) were similar across all three dose groups. Additionally, in all dose groups, most TEAEs were mild-to-moderate in severity. The most common TEAEs (≥ 4% of patients in any dose group) were upper respiratory infection, nasopharyngitis, injection-site reaction (ISR), headache, hypertension and urinary tract infection. During the 52-week period, 1Á9% of patients in the Q4W group, 4Á2% of patients in the Q4W/ Q2W dose-adjustment group and 3Á1% of patients in the Q2W group discontinued the study due to adverse events ( Table 3) . The Q2W dose group demonstrated no clinically significant safety findings related to infections or cytopenias. Generally, major adverse cardiovascular events, malignancies and IBD events were uncommon and consistent with rates reported in the UNCOVER trials.
1,2,9 ISRs were mild or moderate in severity. Two ISR events were reported as severe and one patient discontinued treatment thereafter. Approximately 5% of patients in each dose group were reported to have a serious adverse event. In total, three deaths (0Á2%) were reported. Two of the deaths were due to cardiovascular events, one in a patient who had received Q4W dosing and one in a patient who had received Q2W dosing. These patients had histories of cardiovascular disease; both events were independently adjudicated by external reviewers, and the deaths were deemed by the respective investigators to be unrelated to study treatment. The third death was due to a work-related traumatic injury in a patient who had received Q2W dosing and was deemed by the investigator to be unrelated to study treatment.
Discussion
In this trial, 52-week efficacy and safety in patients with moderate-to-severe plaque psoriasis treated continuously with ixekizumab Q2W were evaluated for the first time. PASI 75 and sPGA 0/1 responses were high across all dose groups, demonstrating the overall effectiveness of ixekizumab in the treatment of moderate-to-severe plaque psoriasis. However, these primary efficacy outcomes were significantly higher in the Q2W group compared with the Q4W group. Response rates for complete resolution of overall psoriasis, as well as scalp, nail and palmoplantar regional psoriasis, were high across all dose groups. Safety was also comparable across all dose groups. Increasing dose frequency in patients who had sPGA ≥ 2 at two consecutive visits did not significantly increase response rates in the Q4W/Q2W dose-adjustment group compared with Q4W, except for PASI 90. Only 23Á5% of the patients in the dose-adjustment group met the prespecified criteria, so caution should be exercised for any interpretation of results in this group. Of note, most of the patients who adjusted dose met the up-dosing criteria at week 16.
There were no unexpected safety signals; the pattern of results was consistent with that previously reported in the UNCOVER trials. 1, 9 Importantly, no appreciable safety differences between the Q2W and Q4W dose groups were noted during the 52-week study period. Frequency of overall infections was lower in patients treated with Q2W vs. Q4W, and there were no differences in Candida infections among the different dose groups. ISRs were significantly higher in the Q2W group compared with the Q4W/Q2W dose-adjustment group but not when compared with the Q4W group. IXORA-P had a high completion rate, with 88% of patients completing this 52-week study, and there were no differences between the dose groups, further supporting the safety and tolerability of all ixekizumab dose groups. IXORA-P had some limitations. Because a large proportion of patients responded, most patients in the dose-adjustment group continued Q4W dosing, making definitive conclusions about the benefits of adjusting dose to Q2W challenging. Additionally, the lack of placebo group may have led to slightly higher response rates; although overlapping dose groups between the UNCOVER and IXORA-P trials had comparable results for efficacy outcomes at week 12 for Q2W and Q4W dose groups (all UNCOVER trials), 1,2 and week 52 for continuous Q4W dose groups (UNCOVER-3). 2 Finally, the dosing regimens for IXORA-P were chosen based on the 12-week results from the pivotal UNCOVER studies. Owing to the timing of the design of this study, the current recommended label dose was not included, so direct comparisons beyond 12 weeks between continuous Q2W dosing vs. Q2W/ Q4W label dosing cannot be drawn. There were also some strengths to IXORA-P. The large size of this trial provided sufficient power to examine differences between Q4W and Q2W groups over 52 weeks. In contrast to two of the three UNCOVER trials, where re-randomization and evaluation of patients in the long-term periods were dependent on sPGA 0/1 response at week 12, IXORA-P evaluated all patients over time, regardless of their week 12 responses. Results from this trial answer the important clinical question of efficacy and safety in patients with moderate-tosevere psoriasis treated continuously with ixekizumab Q2W for a longer term (compared with continuous Q4W dosing), which has not been previously addressed in any other ixekizumab study.
Efficacy and safety for 52-week continuous Q2W dosing was established. Q2W dosing demonstrated higher efficacy than Q4W dosing for all evaluated sPGA and PASI outcomes. e Primary analysis method for categorical binary efficacy measures was logistic regression analysis with dosing regimen, country and baseline weight category (< 80 kg, ≥ 80 to < 100 kg, or ≥ 100 kg) as factors (unless there was a lack of convergence, in which case the P-values were calculated using Fisher's exact test).
The long-term safety profile of Q2W dosing was comparable to Q4W dosing and was consistent with the overall safety profile of ixekizumab. The benefits of the Q4W/Q2W doseadjustment group compared with those in the Q4W dose group were not conclusive, as only around a quarter of patients in this group met the dose-adjustment criteria. Higher responses at week 12 for Q2W compared with Q4W dose groups were generally consistent with those seen in the One case of moderate oesophageal candidiasis occurred in a patient treated Q2W, who had received antibiotics 10 days earlier to treat sepsis. This patient was discontinued from the study owing to sepsis; both sepsis and candidiasis resolved with treatment. The other cases were mild in severity.
f Broad category of ISR included ISR, erythema, pain, swelling, pruritus, bruising, urticaria, induration, haemorrhage, rash, oedema, inflammation, irritation, hypersensitivity and mass.
g Numbers reflect potential cases. Two cases were adjudicated as probable (Q4W and Q2W), one case adjudicated as possible (Q2W), one patient (Q4W/Q2W) adjudicated as microcytic colitis and not IBD, and there was not sufficient information available for two patients (Q2W) to confirm IBD.
h % is based on the patients who have baseline and at least one post-baseline neutrophil assessment: Nx = 305 (IXE Q4W), Nx = 299 (IXE Q4W/Q2W), Nx = 603 (IXE Q2W).
UNCOVER trials; nonetheless, the clinical relevance of longterm Q2W vs. Q2W/Q4W dosing, which is the recommended label dose, is still unknown.
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